Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial

作者：Hans‐Jürgen Stellbrink, José Ramón Arribas, Jeffrey L. Stephens, Helmut Albrecht, Paul E. Sax, Franco Maggiolo, Catherine Creticos, Claudia Martorell, Xuelian Wei, Rima Acosta, Sean E Collins, Diana M. Brainard, Hal Martin · 发表于：The Lancet HIV · 年份：2019 · DOI：10.1016/s2352-3018(19)30080-3 · 被引用次数：145 · 研究领域：HIV-related health complications and treatments、HIV/AIDS drug development and treatment、HIV/AIDS Research and Interventions